[Home ] [Archive]   [ فارسی ]  
:: Main :: About :: Current Issue :: Archive :: Search :: Submit :: Contact ::
Main Menu
Journal Information::
Articles archive::
Publication Ethics::
Peer Review Process::
Indexing Databases::
For Authors::
For Reviewers::
Contact us::
Site Facilities::
Google Scholar Metrics

Citation Indices from GS

AllSince 2019

Search in website

Advanced Search
Receive site information
Enter your Email in the following box to receive the site news and information.
Registered in



:: Volume 31, Issue 3 (8-2023) ::
Journal of Ilam University of Medical Sciences 2023, 31(3): 76-86 Back to browse issues page
Investigating the therapeutic effect of doxorubicin and resveratrol on MCF7 breast cancer cells
Shima Zorati pour1 , Atousa Moradzadegan * 2
1- Dept of Experimental Sciences, Dezful Branch, Islamic Azad University, Dezful, Iran
2- Dept of Experimental Sciences, Dezful Branch, Islamic Azad University, Dezful, Iran , A.moradzadegan@iaud.ac.ir
Abstract:   (606 Views)
Introduction: Doxorubicin (DOX), an anthracycline antibiotic, is one of the most effective anticancer agents used to treat breast cancer. Multidrug resistance is a major problem in the treatment of breast cancer, and researchers have tried to find an efficient strategy to overcome it. In this study, the synergistic anticancer effects of resveratrol (RSV) and DOX on human breast cancer cell lines (MCF-7) were investigated.
Material & Methods: This research was conducted in 2021-2022 in Afra Laboratory (Tehran, Iran). MCF-7 breast epithelial cells were treated with concentrations of 12.5, 25, 50, 100, and 200 μg/ml RSV for 24, 48, and 72 h, and then the wells containing the cells of this group were treated with different doses of DOX (0.25, 0.5, 2.5, 1, and 5 μg/ml for 24, 48, and 72 h). Afterward, the survival rate of the cell was evaluated using MTT assay and flow cytometry methods.
Findings: The results showed that the effect of resveratrol was less than 50% after 24 hours, indicating the effective role of time. In general, the antioxidant property of resveratrol decreased with an increase in concentration, so that the highest percentage of radical inhibition was recorded at a concentration of 25 μg/ml. The percentage of inhibition by DOX was also higher than the inhibition by RSV. However, for both samples, the percentage of radical inhibition decreased with increasing concentration.
Discussion & Conclusion: Resveratrol treatment increased the cytotoxic activity of DOX against breast cancer cell growth when administered concurrently or 24 h before DOX. These results suggested that treatment with a combination of RSV and DOX might be a useful strategy to enhance the efficacy of DOX by promoting the intracellular accumulation of DOX and reducing multidrug resistance in human breast cancer cells.

Keywords: Breast cancer, Doxorubicin, MCF-7, Resveratrol
Full-Text [PDF 964 kb]   (236 Downloads)    
Type of Study: Research | Subject: Physical Education
Received: 2022/11/27 | Accepted: 2023/05/23 | Published: 2023/09/6
1. Jazayeri S SS, Ramezani R, Kaviani A. Incidence of primary breast cancer in Iran: Ten-year national cancer registry data report. Cancer Epidemiol 2015;39: 519-27. doi: 10.1016/j.canep.2015.04.016.
2. Faraji SN, Mojtahedi Z, Ghalamfarsa G, Takhshid MA. N-myc downstream-regulated gene 2 overexpression reduces matrix metalloproteinase-2 and-9 activities and cell invasion of A549 lung cancer cell line in vitro. IJBMS 2015;18: 773.
3. Comstock C GC, Newstead G, Snyder B, Gareen I, Bergin J, et al. Comparison of abbreviated breast MRI vs digital breast tomosynthesis for breast cancer detection among women with dense breasts undergoing screening. JAMA 2020;323: 746-56. doi: 10.1001/jama.2020.0572.
4. Malmgren J HM, Atwood M, Kaplan H. Examination of a paradox: recurrent metastatic breast cancer incidence declines without improved distant disease survival: 1990-2011. Breast Cancer Res Treat 2019;174: 505-14. doi: 10.1007/s10549-018-05090-y.
5. Carlino M VV, Girgis C, Giannarelli D, Guminski A, Festino L, et al. Cessation of targeted therapy after a complete response in BRAF-mutant advanced melanoma: a case series. Br J Cancer 2016:115:1280-4. doi: 10.1038/bjc.2016.321.
6. Thorn C OC, Marsh S, Hernandez-Boussard T, McLeod H, Klein T, et al. Doxorubicin pathways: pharmacodynamics and adverse effects. Pharmacogenet Genomics 2011; 21: 440. doi: 10.1097/FPC.0b013e32833ffb56.
7. Nagai K FS, Otani K, Nagamine Y, Omotani S, Hatsuda Y, et al. Prevention of doxorubicin-induced renal toxicity by theanine in rats. Pharmacology 2018;101: 219-24. doi: 10.1159/000486625.
8. Brown T SD, Allen A. Implications of Breast Cancer Chemotherapy-Induced Inflammation on the Gut, Liver, and Central Nervous System. Biomedicines 2021;9: 189. doi: 10.3390/biomedicines9020189.
9. Alshelleh M PJ, John V, Rishi A, Bernstein D, Roth N. Olaparib-Induced Immune-Mediated Liver Injury. ACG Case Rep J 2022;9. doi: 10.14309/crj.0000000000000735.
10. Liu H DS, Han L, Ren Y, Gu J, He L, et al. Mesenchymal stem cells, exosomes and exosome-mimics as smart drug carriers for targeted cancer therapy. Colloids Surf B Biointerfaces 2022;209: 112163. doi: 10.1016/j.colsurfb.2021.112163.
11. Majolo F DL, Marmitt D, et al. Medicinal plants and bioactive natural compounds for cancer treatment: Important advances for drug discovery. Phytochem Lett 2019;31, 196-207. doi: 10.1016/j.phytol.2019.04.003.
12. Kritikos S PK, Draganidis D, et al. Effect of whey vs. soy protein supplementation on recovery kinetics following speed endurance training in competitive male soccer players: a randomized controlled trial. J Int Soc Sports Nutr 2021; 18:23. doi: 10.1186/s12970-021-00420-w.
13. Wu P LY, Kuo Y, Tsai S, Lin C. Preparation and evaluation of novel transfersomes combined with the natural antioxidant resveratrol. Molecules 2019;24: 600. doi: 10.3390/molecules24030600.
14. Kra G DJ, Gabay H, Yosefi S, Zachut M. Antioxidant Resveratrol Increases Lipolytic and Reduces Lipogenic Gene Expression under In Vitro Heat Stress Conditions in Dedifferentiated Adipocyte-Derived Progeny Cells from Dairy Cows. Antioxidants 2021;10: 905. doi: 10.3390/antiox10060905.
15. Tripathy DR, Panda A, Dinda AK, Dasgupta S. Positional preferences in flavonoids for inhibition of ribonuclease A: Where "OH" where? Proteins 2021; 89:577-87. doi: 10.1002/prot.26043.
16. Yang R, Dong H, Jia S, Yang Z. Resveratrol as a modulatory of apoptosis and autophagy in cancer therapy. Clin Transl Oncol 2022; 24:1219-30. doi: 10.1007/s12094-021-02770-y.
17. Abdelwahab Yousef AJ. Male Breast Cancer: Epidemiology and Risk Factors. Semin Oncol 2017; 44:267-72. doi: 10.1053/j.seminoncol.2017.11.002.
18. Zhang W, Jiang H, Chen Y, Ren F. Resveratrol chemosensitizes adriamycin-resistant breast cancer cells by modulating miR-122-5p. J Cell Biochem 2019;120:16283-92. doi: 10.1002/jcb.28910.
19. Gomes BAQ, Silva JPB, Romeiro CFR, Dos Santos SM, Rodrigues CA, Gonçalves PR, et al. Neuroprotective Mechanisms of Resveratrol in Alzheimer's Disease: Role of SIRT1. Oxid Med Cell Longev 2018; 2018:8152373. doi: 10.1155/2018/8152373.
20. Griñán-Ferré C, Bellver-Sanchis A, Izquierdo V, Corpas R, Roig-Soriano J, Chillón M, et al. The pleiotropic neuroprotective effects of resveratrol in cognitive decline and Alzheimer's disease pathology: From antioxidant to epigenetic therapy. Ageing Res Rev 2021; 67:101271. doi: 10.1016/j.arr.2021.101271.
21. Le Corre L, Chalabi N, Delort L, Bignon YJ, Bernard-Gallon DJ. Differential expression of genes induced by resveratrol in human breast cancer cell lines. Nutr Cancer 2006; 56:193-203. doi: 10.1207/s15327914nc5602_10.
22. Chen C, Lu L, Yan S, Yi H, Yao H, Wu D, et al. Autophagy and doxorubicin resistance in cancer. Anticancer Drugs 2018; 29:1-9. doi: 10.1097/CAD.0000000000000572.
23. Tan Y, Wei X, Zhang W, Wang X, Wang K, Du B, et al. Resveratrol enhances the radiosensitivity of nasopharyngeal carcinoma cells by downregulating E2F1. Oncol Rep 2017; 37:1833-41. doi: 10.3892/or.2017.5413
Send email to the article author

Add your comments about this article
Your username or Email:


Ethics code: ۹۸۰۰92455

XML   Persian Abstract   Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Zorati pour S, Moradzadegan A. Investigating the therapeutic effect of doxorubicin and resveratrol on MCF7 breast cancer cells. J. Ilam Uni. Med. Sci. 2023; 31 (3) :76-86
URL: http://sjimu.medilam.ac.ir/article-1-7794-en.html

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Volume 31, Issue 3 (8-2023) Back to browse issues page
مجله دانشگاه علوم پزشکی ایلام Journal of Ilam University of Medical Sciences
Persian site map - English site map - Created in 0.16 seconds with 41 queries by YEKTAWEB 4654